Repligen (RGEN) Misses Q2 EPS by 2c; offers guidance

Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.37, $0.02 worse than the analyst estimate of $0.39. Revenue for the quarter came in at $182 million versus the consensus estimate of $175.35 million.

GUIDANCE:

Repligen sees FY2025 EPS of $1.65-$1.72, versus the consensus of $1.68. Repligen sees FY2025 revenue of $715-735 million, versus the consensus of $710.2 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Edison Int'l (EIX) call put ratio 2.1 calls to 1 put as share price up 8.6%
• Amazon (AMZN) call put ratio 1.6 calls 1 put as share price down 2.1%